Hypertension, Lipid Disorders, Vascular Inflammation, Endothelial Dysfunction

CRS on track of the hemodynamic derailment

Endothelial dysfunction could be an early marker of cardiovascular risks


Hypertension, lipid disorders, vascular inflammation, and endothelial dysfunction are important drivers of atherosclerosis and cardiovascular disease. High blood pressure, in turn, is associated with vascular inflammation and endothelial dysfunction. Thus, endothelial dysfunction might even be an early marker of atherosclerosis and cardiovascular risks.

The underlying causes for the occurrence of structural changes in the vessel wall such as an increase in intima media thickness or the appearance of atherosclerotic plaques are well studied. However, long before this becomes apparent, endothelial dysfunction could be found.

In fact, the decline of endothelial function is an aging process that may be accelerated by an increase in shear stress (RR / related to high blood pressure), inflammation, atherogenic lipid profiles, or insulin resistance. And the measurement result of the endothelial function is considered a valuable biomarker for estimating a patient’s cardiovascular risk.

There is more: Hypertension is a complex disease. 90 percent of patients with high blood pressure are categorized as patients with essential arterial hypertension. Now, in recent years, a close association between essential arterial hypertension, vascular inflammation and endothelial dysfunction has been demonstrated. However, it is still unclear what is cause or effect in this triade.

With CRS, your clinical trial is in best hands

The constant care of a powerful CRS proprietary database of volunteers and patients together with a solid network of collaborating medical specialists and office-based family doctors are the key of our highly effective recruitment of healthy volunteers or patients with cardiovascular disease.

CRS-owned excellent equipped and carefully quality controlled Early Phase Clinical Trial Units are a reliable guarantee for CRS-customers for a conduct of the trial complying with all regulatory requirements of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). 

Together with carefully selected external clinical centers of excellence we at CRS can provide a wide range of studies bridging from preclinical evidence to the proof of concept in healthy humans or patients with cardiovascular disease.

CRS’ experienced scientists, statisticians and medical writers can provide essential support in creating powerful study outlines or writing the study protocols in preparation of a study, as well as in finalizing study reports and drafting manuscripts for publication in scientific journals after completion of the clinical trial. A large number of scientific papers published in international peer-reviewed journals are proof of our outstanding expertise in this therapeutic area.

CRS is highly dedicated to cardiometabolic research

CRS Group Mannheim

CRS is highly dedicated to cardiometabolic research with a vision to improve the population’s cardiovascular health. Numerous pharmacological approaches are underway to improve treatment options for hypertension, lipid disorders, obesity, insulin resistance, or vascular inflammation. To significantly aid the development of these treatments, CRS has established a battery of biomarkers to assess endothelial and vascular function, such as:

  • Ultrasound measurement of
  • Intima Media Thickness (IMT)
  • Flow Mediated Dilatation (FMD)
  • Microcvascular Skin Laser Doppler assessments with
  • Actylcholin Iontophoresis
  • Nitrite Oxide Iontophoresis
  • Postischemia
  • Laser Speckle Imaging
  • Arterial Tonometry with
  • Pulse Wave Velocity (PWV)
  • Augmentation Index (AiX@75)
  • 24-hour blood pressure monitoring
  • 24-hour ECG holter monitoring
  • Retinal Microvascular Function
  • Retinal Endothelial Function (Flicker)
  • Laboratory biomarkers
    • cGMP
    • ICAM, VCAM
    • MMP-9
    • IL-6, IL-1ß, TNF-alpha